Search - tctmd.com

Displaying 1 - 20 of 36

Sort: Relevancy | Date

News Daily News

Year in Review: Evidence Around AI in Cardiology Grows

Todd Neale

December 23, 2025

News Daily News

Early Combo Therapy With Ezetimibe Lowers MACE Risk After MI

Michael O'Riordan

April 22, 2025

$Coronary Sinus Reducer Eases Symptoms in Refractory Angina: ORBITA-COSMIC$

News Conference News ACC 2024

Coronary Sinus Reducer Eases Symptoms in Refractory Angina: ORBITA-COSMIC

Michael O'Riordan

April 08, 2024

News Opinion CV Team Dispatch

August 2023 News Roundup

L.A. McKeown

August 01, 2023

News Daily News

New Data Support Tighter Air Pollution Standards to Reduce CV Events

L.A. McKeown

February 27, 2023

NY State to Exclude Emergency PCI Cases From Public Outcomes Reports

News Daily News

NY State to Exclude Emergency PCI Deaths From Physician-Level Public Reports

Todd Neale

January 04, 2023

News Daily News

Statin Intolerance Overestimated—Only ‘Small Number’ Get Side Effects: Meta-analysis

Michael O'Riordan

February 18, 2022

News Features

Roughly 80% of ESC Guideline Writers Have Financial COIs

Michael O'Riordan

April 01, 2021

News Daily News

Implantable Cardiac Monitor May Reduce Delays to Hospital in High-Risk ACS

L.A. McKeown

October 15, 2019

News Daily News

Ezetimibe With Statin Therapy: Biggest Bang in Higher-Risk ACS Patients

Michael O'Riordan

August 22, 2019

News Conference News CRT 2019

New ALERTS Data Support Use of Implantable Cardiac Monitor in High-Risk ACS Patients—With Caveats

Yael L. Maxwell

March 03, 2019

News Daily News

European Regulators Strike Secondary Prevention Claim for Omega-3 Drugs

Shelley Wood

December 18, 2018

News Conference News TCT 2018

Twitter, Bias, and Trial Tweaks: ISCHEMIA Invites Debate on Study Designs and Endpoint Combos

Michael O'Riordan

October 02, 2018

News Daily News

Rivaroxaban Offers Net Reduction in Fatal or Irreversible Events in ACS: ATLAS ACS-2 TIMI-51

Michael O'Riordan

July 06, 2018

News Daily News

Implantable Cardiac Monitor for High-Risk ACS Patients Wins FDA Approval

Michael O'Riordan

May 08, 2018

News Daily News

FDA Advisory Panel Says Celecoxib Is as Safe for Heart as Ibuprofen and Naproxen

Michael O'Riordan

April 25, 2018

News Daily News

FDA Advisors Take Fresh Look at Celecoxib Safety as PRECISION Aspirin Analysis Unveiled

Michael O'Riordan

April 24, 2018

News Conference News AHA 2017

Survey Says: Interventionalists Believe Public Reporting Leads to High-Risk PCI Avoidance, Upcoding

Yael L. Maxwell

November 15, 2017

News Daily News

Fish Oils: Yes for HF and Secondary Prevention, No for the General Population, Says AHA

Michael O'Riordan

March 15, 2017

News Daily News

Lowering LDL With Statins and Other Selected Agents Should Be Focus of CVD Risk Reduction, Analysis Implies

Michael O'Riordan

September 27, 2016

Advertisement

Year in Review: Evidence Around AI in Cardiology Grows

Early Combo Therapy With Ezetimibe Lowers MACE Risk After MI

Coronary Sinus Reducer Eases Symptoms in Refractory Angina: ORBITA-COSMIC

August 2023 News Roundup

New Data Support Tighter Air Pollution Standards to Reduce CV Events

NY State to Exclude Emergency PCI Deaths From Physician-Level Public Reports

Statin Intolerance Overestimated—Only ‘Small Number’ Get Side Effects: Meta-analysis

Roughly 80% of ESC Guideline Writers Have Financial COIs

Implantable Cardiac Monitor May Reduce Delays to Hospital in High-Risk ACS

Ezetimibe With Statin Therapy: Biggest Bang in Higher-Risk ACS Patients

New ALERTS Data Support Use of Implantable Cardiac Monitor in High-Risk ACS Patients—With Caveats

European Regulators Strike Secondary Prevention Claim for Omega-3 Drugs

Twitter, Bias, and Trial Tweaks: ISCHEMIA Invites Debate on Study Designs and Endpoint Combos

Rivaroxaban Offers Net Reduction in Fatal or Irreversible Events in ACS: ATLAS ACS-2 TIMI-51

Implantable Cardiac Monitor for High-Risk ACS Patients Wins FDA Approval

FDA Advisory Panel Says Celecoxib Is as Safe for Heart as Ibuprofen and Naproxen

FDA Advisors Take Fresh Look at Celecoxib Safety as PRECISION Aspirin Analysis Unveiled

Survey Says: Interventionalists Believe Public Reporting Leads to High-Risk PCI Avoidance, Upcoding

Fish Oils: Yes for HF and Secondary Prevention, No for the General Population, Says AHA

Lowering LDL With Statins and Other Selected Agents Should Be Focus of CVD Risk Reduction, Analysis Implies

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content